Table 2

Immunogenicity summary

End of period II (Withdrawal phase)End of period III (Reintroduction phase)*
Period II SC abatacept (n=40)Period II SC placebo (n=80)Period II SC abatacept(n=40)Period II SC placebo(n=79)
Anti-abatacept, n/N (%)0/37 (0)1/71 (1.4)0/38 (0)0/73 (0)
95% CI0.0 to 4.1
Anti-CTLA4-T, n/N (%)0/38 (0)6/73 (8.2)1/38 (2.6)2/73 (2.7)
95% CI1.9 to 14.50.0 to 7.70.0 to 6.5
Total, n/N (%)0/38 (0)7/73 (9.6)1/38 (2.6)2/73 (2.7)
95% CI2.8 to 16.30.0 to 7.70.0 to 6.5
Estimate of difference, % (95% CI)9.59 (0.83 to 18.34)0.11 (–8.21 to 8.43)
p Value0.119
  • * All patients received SC abatacept during period III, with results shown by period II treatment group.

  • Patients received intravenous placebo loading at the start of period III.

  • Patients received intravenous abatacept or intravenous placebo (1:1 ratio) loading at the start of period III.

  • SC, subcutaneous.